Prevalence of Metabolic Syndrome in COPD Patients and Its Consequences

Marie-Kathrin Breyer, Martijn A. Spruit, Corrine K. Hanson, Frits M. E. Franssen, Lowie E. G. Vanfleteren, Miriam T. J. Groenen, Piet L. B. Bruijnzeel, Emiel F. M. Wouters, Erica P. A. Rutten

1 Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, the Netherlands
2 Program Development Center (CIRO), Center of Expertise for Chronic Organ Failure, Horn, the Netherlands
3 Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Pulmonary Epidemiology, Otto Wagner Hospital, Vienna, Austria
4 Division of Medical Nutrition Education, School of Allied Health Professions, University of Nebraska Medical Center, Omaha, Nebraska, United States of America
5 Inflammation Neuroscience and Respiratory, AstraZeneca, Molndal, Sweden

Abstract

Background: The prevalence of metabolic syndrome in COPD patients and its impact on patient related outcomes has been little studied. We evaluated the prevalence of metabolic syndrome and clinical and functional characteristics in patients with COPD and healthy subjects.

Methods: 228 COPD patients and 156 healthy subjects were included. Metabolic syndrome was defined using criteria of the IDF. In all patients spirometry, body composition, functional exercise performance, and mood and health status were assessed. Groups were stratified for BMI and gender.

Results: Metabolic syndrome was present in 57% of the COPD patients and 40% of the healthy subjects. After stratification for BMI, presence of metabolic syndrome in patients with a BMI ≥25 kg/m² was higher than in healthy peers. Patients with metabolic syndrome and a BMI <25 kg/m² had higher BMI, fat free mass index and bone mineral density, and a lower 6MWD than the BMI matched patients without metabolic syndrome. Spirometry, maximal ergometry, mood and health status, and blood gases were not different between those groups. In COPD patients with metabolic syndrome self-reported co-morbidities and medication use were higher than in those without.

Conclusion: Metabolic syndrome is more prevalent in overweight or obese COPD patients than in BMI matched healthy subjects. Metabolic syndrome did not additionally impact patients’ functional outcomes, but did impact the prevalence of co-morbidities.

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive. Additionally, exacerbations and co-existing morbidities contribute to the overall severity in the individual patient [1]. Indeed, cardiovascular co-morbidities are common in COPD [2] and are associated with an increased mortality risk [3,4]. So far, the underlying mechanisms are only partially understood. In addition to smoking, other factors may contribute including advanced age, medications, systemic inflammation and metabolic disturbances.

Metabolic syndrome is a common metabolic disorder defined as a complex of interrelated cardiovascular risk factors [5]. Metabolic syndrome is age dependent [6] and has been related to several other health conditions [7] and an increased mortality risk [8]. In addition, metabolic syndrome has clinically relevant negative effects on subjects exercise capacity [9], as well as on health status [10], while protective effects are described on bone mineral density (BMD) [11].

To date, the prevalence of metabolic syndrome in COPD patients compared to healthy subjects has been studied scarcely [12]. Marquis and colleagues reported an increased prevalence in 38 COPD patients compared to 34 healthy subjects (47% vs. 21%, respectively) [13]. A comparable prevalence of metabolic syndrome in COPD was reported by Watz and colleagues [14], but no healthy control group was included in this study.

COPD patients with metabolic syndrome are physically less active and have increased levels of systemic inflammation.
compared to COPD patients without metabolic syndrome [14]. To date it remains largely unknown whether and to what extent other clinical outcomes, like spirometry, functional exercise performance, mood and health status, and the prevalence of cardiovascular co-morbidity might differ between COPD patients with and without metabolic syndrome. Therefore, we think it is of great interest to get more insight of the impact of metabolic syndrome on COPD patients' clinical outcomes in order to better characterise this subgroup of COPD patients.

In the present study we evaluated the prevalence of metabolic syndrome in COPD patients compared to healthy subjects. We hypothesize that the prevalence of metabolic syndrome is higher in the patients. In addition, clinical and functional characteristics of COPD patients with and without metabolic syndrome were studied.

Methods

Study population

Data were prospectively collected in 228 clinically stable COPD patients and 156 healthy subjects from 2007–2012. All patients and 55 healthy subjects were recruited as part of the CIROCO study and 101 control subjects were recruited from another observational prospective study. For both studies, inclusion criteria for the COPD patients were: diagnosis of COPD, GOLD I–IV [15] and no respiratory tract infection or exacerbation at least 4 weeks prior to the study. Exclusion criteria for both groups were any kind of oncologic pathology less than 5 years prior to the study.

Ethics statement

Study 1 (CIROCO study): Ethical approval number: 10-3-067. Medical ethical committee of the Maastricht University Medical Centre. Study 2 ethical approval number: 10-3-033, Medical ethical committee of the Maastricht University Medical Centre, www.controlled-trials.com, ISRCTN86049077. All participants gave written informed consent.

International Diabetes Federation (IDF) definition of metabolic syndrome [5]

- Waist circumference (WC) $\geq 94$ cm in European men or $\geq 80$ cm in European women
- Plus two of the following:
  - glucose $\geq 100$ mg/dL (5.6 mmol/L) or previously diagnosed type II diabetes;
  - triglyceride $\geq 150$ mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality;
  - high density lipoprotein (HDL), $40$ mg/dL (1.03 mmol/L) in men or $50$ mg/dL (1.29 mmol/L) in women or specific treatment for this lipid abnormality;
  - systolic blood pressure $\geq 130$ mmHg and/or diastolic blood pressure $\geq 85$ mmHg or treatment of previously diagnosed hypertension;

Lung function and arterial blood gases

Lung function parameters were collected using standardized spirometry (Masterlab, Viasys, Germany). The degree of severity
of airflow limitation was classified according to the GOLD guidelines [15]. Arterial oxygen tensions (PaO2) and arterial carbon dioxide tension (PaCO2) have been analyzed in the patients only.

Anthropometric parameters

Fat free mass index (FFMI) and bone mineral density (BMD) have been assessed using a dual x-ray absorptiometry (DEXA) scan (Lunar Prodigy; GE Healthcare, Madison, WI, USA). FFMI was calculated as: FFM in kilogram divided by squared height in meters. Low FFM was defined as FFMI $\leq 15$ (females) or $\leq 16$ (males) kg/m$^2$. BMD has been defined by a T-score (hip and lumbar spine) $< -2.5$.

Exercise capacity and mood status

In patients peak cycling load has been assessed by incremental ergometry cycling test and functional exercise capacity by six-minute walking distance test (6MWD). The St. George Respiratory Questionnaire (SGRQ) has been used to assess disease-specific health status [16]. Assessment of mood status has been done using the Hospital Anxiety and Depression Scale (HADS) [17].

### Table 1. Baseline characteristics of the total study population.

|                        | COPD patients (n = 228) | healthy subjects (n = 156) |
|------------------------|-------------------------|---------------------------|
| Gender, %male          | 59                      | 45*                       |
| age, years             | 63.7±7.1                | 60.1±7.4*                 |
| FEV1, %pred            | 52.8±18.6               | 120.4±15.8*               |
| FVC, %pred             | 96.1±19.1               | 122.8±21.3*               |
| FEV1/FVC               | 40.9±12.2               | 78.1±6.5*                 |
| smoking status         |                         |                           |
| never smoker, %        | 0                       | 77*                       |
| former smoker, %       | 73                      | 23*                       |
| current smoker, %      | 27                      | 0*                        |
| Pack years, n$^a$      | 43.0 (29.4–58.5)        | 3.5 (0.0–15.3)*           |
| BMI, kg/m$^2$          | 26.2±5.1                | 27.3±4.2$^2$              |
| FFMI, kg/m$^2$         | 17.0±2.4                | 17.9±3.6*                 |
| Waist circumference, cm| 98.5±14.3               | 93.9±10.7*                |
| Plasma glucose level, mmol/L | 5.8±1.2                | 5.6±0.7                   |
| Plasma triglyceride level, mmol/L | 1.5±0.9                | 1.5±1.1                   |
| Plasma HDL level, mmol/L | 1.7±0.5                 | 1.8±0.5$^3$               |
| Systolic blood pressure, mmHg | 138.6±21.4              | 142.7±20.3                |
| Diastolic blood pressure, mmHg | 82.2±9.7               | 84.3±9.1$^4$              |
| High waist circumference$^b$, %     | 79                      | 79                        |
| High glucose level$^b$, %     | 49                      | 45                        |
| High triglyceride level$^b$, %     | 31                      | 22                        |
| High HDL level$^b$, %     | 10                      | 8                         |
| High systolic blood pressure$^b$, %     | 61                      | 75*                       |
| High diastolic blood pressure$^b$, %     | 33                      | 46*                       |
| Metabolic syndrome$^b$, %   | 57                      | 40*                       |

Data are presented: mean ± SD, percentages or $^a$median (interquartile range) if data were not normal distributed.

Other symbols:
- $^a$p<0.01.
- $^b$p<0.05 compared with COPD patients.
- $^1$according to the IDF.

Additional parameters

The Modified Medical Research Council (MRC) dyspnoea scale, subjects’ smoking status, number of pack years, the use of long-term oxygen therapy (LTOT), the Charlson Co-morbidity Index (CCI) [18] and current pharmacological treatment were recorded.

Statistical analyses

Besides whole group comparison, both the patient and healthy subject groups were stratified for BMI (cut-off of 25 kg/m$^2$) and for gender to evaluate the prevalence of the metabolic syndrome. Categorical variables are described as frequencies, while continuous variables were checked for normality and described as mean ± SD or median (interquartile range; for pack years). Evaluation of group differences (patients vs. healthy subjects, patients with vs. without metabolic syndrome) in means for continuous variables was done using the Unpaired Student’s t-test, and for categorical variables the chi-square test. Logistic regression was performed to
test whether COPD patients had a higher risk of having metabolic syndrome after correction for age, gender and BMI. All analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 20 for Windows. A \( p \)-value of \( \leq 0.05 \) was considered significant.

**Results**

**Prevalence of metabolic syndrome and its components**

A diagram of participant flow is shown in **Figure 1**. The COPD patients were characterised by moderate to severe airflow limitation (**Table 1**). Compared to healthy, patients were slightly older, had a higher number of pack years and male gender was predominant. While BMI and FFMI were lower, WC was higher in the patients. Plasma HDL concentration and diastolic BP were lower in the patients. Prevalence of a high systolic and diastolic BP, one of the criteria of metabolic syndrome, was more prevalent in healthy than in the patients, but metabolic syndrome was more prevalent in the patients than in healthy subjects. After stratification for BMI: the subgroup of patients with a BMI \( \geq 25 \) kg/m\(^2\) were matched for BMI with their healthy peers, but BMI was lower in the subgroup of patients with BMI \( <25 \) kg/m\(^2\) compared to their healthy peers (**Table 2**). Further, in the subgroups of subjects with BMI \( <25 \) kg/m\(^2\), WC was higher and plasma HDL concentration was lower in patients than in healthy, but the prevalence of the metabolic syndrome was comparable. In the logistic regression on metabolic syndrome, COPD patients had a 60% more chance of having metabolic syndrome than control subjects after correction for age, gender and BMI (**Table 3**). **Figure 2 and 3** provide an overview of the prevalence of metabolic syndrome and its components in patients and healthy subjects after stratification for gender and BMI (**Table 3**).

**Table 2.** Body composition and criteria of metabolic syndrome of the study population by BMI.

|                  | BMI <25 kg/m\(^2\) |                  | BMI \( \geq 25 \) kg/m\(^2\) |                  |
|------------------|---------------------|------------------|-----------------------------|------------------|
| BMI, kg/m\(^2\)  | COPD patients (n = 97) | healthy subjects (n = 47) | COPD patients (n = 131) | healthy subjects (n = 109) |
|                  | 21.7±1.6  | 23.0±1.5\(^*\) | 29.4±3.9 | 29.1±3.5 |
| FFMI, kg/m\(^2\) | 15.3±1.5  | 15.8±1.9\(^*\) | 18.3±2.1 | 18.8±3.7 |
| Waist circumference, cm | 87.4±10.6 | 83.3±7.7\(^*\) | 107±10.7 | 98.5±8.2\(^*\) |
| Plasma glucose level, mmol/L | 5.5±0.9 | 5.4±0.6 | 6.0±1.3 | 5.7±0.7\(^\dagger\) |
| Plasma triglyceride level, mmol/L | 1.3±0.6 | 1.2±0.6 | 1.7±1.0 | 1.6±1.3 |
| Plasma HDL level, mmol/L | 1.8±0.5 | 2.0±0.5\(^\dagger\) | 1.4±0.4 | 1.7±0.4 |
| Systolic blood pressure, mmHg | 136.5±49.9 | 135.1±18.5 | 140±22.3 | 146±20.2\(^*\) |
| Diastolic blood pressure, mmHg | 82.3±9.5 | 80.2±8.9 | 82.2±9.9 | 86.1±8.6\(^*\) |
| High waist circumference\(^5\), % | 49 | 57 | 100 | 88\(^*\) |
| High glucose level\(^1\), % | 41 | 36 | 55 | 49 |
| High triglyceride level\(^5\), % | 20 | 17 | 40 | 25\(^\dagger\) |
| High HDL level\(^6\), % | 5 | 6 | 13 | 8 |
| High systolic blood pressure\(^5\), % | 55 | 55 | 66 | 83\(^*\) |
| High diastolic blood pressure\(^5\), % | 33 | 23 | 33 | 56\(^\dagger\) |
| Metabolic syndrome\(^5\), % | 29 | 17 | 77 | 50\(^*\) |

Data are presented: mean ± SD or percentages. BMI, body mass index; FFMI, fat free mass index; HDL, high density lipoprotein.

\(^{1}\)according to the IDF.

Other symbols:

\(^{*}\)p < 0.01,

\(^{\dagger}\)p < 0.05 compared with COPD patients.

doi:10.1371/journal.pone.0098013.t002

**Table 3.** Logistic regression with metabolic syndrome as dependent variable.

|                  | OR  | CI          | P-value |
|------------------|-----|-------------|---------|
| Age              | 1.03| 0.99–1.06   | 0.11    |
| Gender (male = 1)| 0.58| 0.37–0.92   | 0.02    |
| BMI (BMI <25 kg/m\(^2\) = 1) | 6.85| 4.13–11.36  | <0.01   |
| Group (COPD = 1) | 0.39| 0.24–0.64   | <0.01   |

The interaction term group*BMI was not significant, so it was excluded from the model. Abbreviations: OR: odds ratio; CI: 95th percentile confident interval.

doi:10.1371/journal.pone.0098013.t003
Characteristics of patients with and without metabolic syndrome

Even after stratification for BMI, the markers of body composition, BMI and FFMI were higher in patients with compared to those without metabolic syndrome (Table 4). Further, in the patients with BMI <25 kg/m², patients with metabolic syndrome had a lower prevalence of low muscle mass and a lower 6MWD compared to patients without metabolic syndrome. In addition, the proportion of patients using statins and BP lowering drugs was higher when having metabolic syndrome. In the patients with BMI ≥25 kg/m², male gender was predominant and BMD of the lumbar spine was higher in the patients with compared to those without metabolic syndrome. Also the proportion of patients with co-morbidities, and the proportion of patients using statins, β-blockers and BP lowering drugs was higher in the patients with compared to those without metabolic syndrome. Other characteristics like spirometry, GOLD stages and combined COPD assessment, peak cycling load, prevalence of osteopenia/osteoporosis, use of LTOT, arterial blood gases, dyspnea, symptoms of anxiety and depression, and health status were similar between COPD patients with and without metabolic syndrome.

Discussion

The present study reports on two important findings: first, metabolic syndrome is more prevalent in overweight to obese patients with COPD compared to BMI matched healthy subjects. Second, the presence of metabolic syndrome in COPD patients had no functional consequences, but it coincided with more cardiovascular co-morbidity and type II diabetes. Fifty seven percent of the COPD patients were diagnosed with metabolic syndrome, a prevalence comparable with previous studies [13,14]. However, this percentage was significantly higher compared to the healthy subjects, despite the presence of a lower BMI. Indeed, after stratification for BMI, the prevalence of metabolic syndrome was significantly higher in the patients compared to the healthy subjects in the group with BMI ≥25 kg/m². According to the IDF, the prevalence of metabolic syndrome is largely driven by abdominal obesity. In fact, it was recently shown that patients with obstructive lung disease have more visceral fat mass compared to healthy subjects [19]. Here, these findings are indirectly confirmed by the observation that even after stratification for BMI patients in both BMI sub-groups have higher WC than their matched healthy peers. It is uncertain why abdominal obesity is more prevalent in COPD patients compared to healthy subjects, but various factors including poor nutrition and an inactive lifestyle may play an important role [19]. It is remarkable that the prevalence of metabolic syndrome is only higher in the patients with BMI ≥25 kg/m². Furthermore, cardiovascular co-morbidity was more prevalent in the patients with metabolic syndrome and BMI ≥25 kg/m². These data imply that BMI contribute to the cardiovascular co-morbidity in COPD on top of metabolic syndrome.
Table 4. Clinical and functional characteristics of the COPD patients by metabolic syndrome.

|                | BMI <25 kg/m² | BMI ≥25 kg/m² |
|----------------|---------------|---------------|
|                | with (n = 28) | without (n = 69) | with (n = 101) | without (n = 30) |
| **age, years** | 64.3±6.6      | 62.9±7.2      | 64.1±7.2      | 63.7±7.3       |
| **BMI**        | 23.2±1.3      | 21.1±2.5*     | 30.1±4.1      | 27.3±2.2*      |
| **MRC**        | 2.3±1.3       | 1.9±1.0       | 2.2±1.1       | 2.0±1.2        |
| **HADS, anxiety** | 6.0±3.8   | 6.5±4.3       | 6.0±3.8       | 7.2±4.2        |
| **LTOT, %**    | 10           | 13            | 13            | 23             |
| **6MWD, m**    | 438.0±122.1   | 491.9±97.3    | 460.4±95.5    | 474.6±125.3    |
| **PVR, %**     | 9.3±1.1       | 9.6±1.1       | 9.5±1.0       | 9.3±1.2        |
| **HADS, depression** | 5.4±3.6   | 5.6±3.4       | 5.8±3.7       | 5.7±3.6        |
| **PGIV, total score** | 52.2±16.2 | 49.8±18.1     | 52.7±16.9     | 50.3±19.7      |
| **SGRQ, symptom score** | 54.8±18.8 | 57.7±21.4     | 55.2±19.9     | 53.4±23.0      |
| **SGRQ, activity score** | 65.6±20.8 | 65.6±23.2     | 71.0±21.0     | 66.7±21.6      |
| **SGRQ, impact score** | 39.3±21.4 | 38.9±21.6     | 41.2±18.0     | 40.0±21.8      |
| **Charlson Co-morbidity Index** | 32 | 22 | 39 | 27 |
| **CVD, %**     | 32           | 22            | 39            | 27             |
| **Myocardial infarct, %** | 4 | 6 | 18 | 0* |
| **Peripheral vascular disease, %** | 14 | 13 | 22 | 13* |
| **Type II diabetes, %** | 7 | 3 | 8 | 3* |
| **Medication use** |               |               |               |               |
| **Inhaled CS, %** | 14 | 12 | 13 | 13 |
| **Oral CS, %**   | 14           | 7             | 8             | 10             |
| **Statins, %**   | 46           | 7*            | 47            | 3*             |
| **Beta-blockers, %** | 21 | 9 | 26 | 7* |
| **Anti-diabetics, %** | 7 | 3 | 6 | 3 |
The presence of metabolic syndrome was independent of the degree of airflow limitation. One other manuscript reported a slightly higher prevalence of metabolic syndrome in mild to moderate COPD patients [14]. In the present study most patients had COPD GOLD stage II or III, but no difference in the prevalence of metabolic syndrome within the various GOLD stages of COPD could be identified. Indeed, in the general population metabolic syndrome is associated with restrictive ventilatory patterns but not with obstructive lung function impairments [20]. This association is mainly driven by abdominal obesity, which is particularly present in patients with moderate airflow obstruction.

In patients with BMI <25 kg/m², patients with metabolic syndrome had lower 6MWD compared to the patients without metabolic syndrome. This is a surprising finding as the prevalence of low muscle mass, which is associated with decreased exercise tolerance [21], was lower in the patients with metabolic syndrome. On the other hand, metabolic syndrome contributes to a lower exercise capacity assessed by treadmill test in healthy subjects [9,22] and lower physical activity levels have been found in COPD patients with compared to those without metabolic syndrome [14]. However, differences in body composition were not taken into account as possible confounder. Interestingly, in the patients with BMI ≥25 kg/m² metabolic syndrome did not affect functional exercise performance.

In the present study the prevalence of osteoporosis in COPD patients ranges from 20% up to 50% depending on BMI. To date no data are available on levels of BMD in COPD patients with metabolic syndrome. In the present study we did not find an association between the prevalence of metabolic syndrome and the prevalence of osteoporosis, but we did find a higher BMD of the lumbar spine in the patients with BMI ≥25 kg/m² and metabolic syndrome. In the NHANES study, performed in the general population it was shown that subjects with metabolic syndrome have higher BMD compared to subjects without metabolic syndrome (after correcting for multiple confounders) and these results were mainly driven by an increased abdominal obesity [11]. Indeed, even a protective effect of criteria of metabolic syndrome against non-vertebral fractures has been described in patients with type II diabetes [23]. This effect could be partly explained by an increased mechanical load on the cortical skeleton [24] and increased insulin levels promoting bone formation due to an increased fat mass [25]. There aside, in COPD it is already shown that circulating leptin, a cytokine produced and secreted by adipocytes, appears to act as a mediator between fat mass and bone mass [26]. More studies should be performed to investigate whether metabolic syndrome in COPD could have a protective effect on osteoporosis.

COPD is known to have a negative impact on the disease-specific health status and the effect increases even more with increased disease severity [27]. Identifying factors related to a decreased health status in COPD are, besides lung function impairment [27], exercise intolerance [28], dyspnoea, anxiety [29], and body composition [30]. In general chronic conditions, such as type II diabetes, hypertension as well as dyslipidemia are well known to affect patients’ health status. Thus, it can be expected that subjects having metabolic syndrome also suffer from an impaired health status [31,32]. In COPD co-morbid conditions might lead to a further decrease in health status. However, results from our study show that COPD patients having metabolic syndrome are not additionally affected in their disease-specific health status.

Finally the latest global strategy for the diagnosis, management and prevention of COPD (GOLD) highlighted the importance of co-morbidities in COPD. In particular, cardiovascular diseases, lung cancer, osteoporosis, depression, and metabolic disorders, such as type II diabetes, as they have a significant impact on prognosis and some of them even have been found to be the most frequent cause of death in mild COPD [1]. The here presented results indicate that having metabolic syndrome increases the co-morbidity index, particularly in those patients with an overweight or obese BMI. Therefore metabolic syndrome has to be identified and treated appropriately in patients with COPD.

The following methodological considerations have to be taken into account: firstly, healthy subjects were slightly younger than the COPD patients. However, it is unlikely that a mean age difference of about 3 years explains the difference in the prevalence of the metabolic syndrome. Secondly, blood pressure of the healthy was relatively high. Indeed, hypertension was the most mentioned co-morbidity among the healthy. Further, subjects were not allowed to take their blood lowering drugs before the tests. Thirdly, no metabolic effects of metabolic syndrome are taken into account in the present study. Neverthe-

| BMI <25 kg/m² | BMI ≥25 kg/m² |
|----------------|----------------|
| **Metabolic syndrome** | **Metabolic syndrome** |
| with (n = 28) | without (n = 69) | with (n = 101) | without (n = 30) |
| Insulin, % | 0 | 0 | 3 | 3 |
| Blood pressure lowering drugs, % | 54 | 28* | 61 | 17* |

Data are mean ± SD or percentages or median (interquartile range) if data were not normal distributed.

FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; BMI, body mass index; FFMI, fat free mass index; BMD, bone mineral density; 6MWD, six minute walking distance; LTOT, long term oxygen therapy; PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension; CVD, cardiovascular disease; inhaled and oral CS, inhaled and oral corticosteroids; MRC, modified Medical Research Council; HADS, Hospital Anxiety and Depression Scale; SGRQ, St. George Respiratory Questionnaire.

* p<0.01,
\( ^\dagger \) p<0.05 compared to patients without the metabolic syndrome.

doi:10.1371/journal.pone.0098013.t004
In conclusion, in contrast to normal weight patients, metabolic syndrome is more prevalent in overweight and obese patients with COPD compared to BMI matched healthy subjects. Both, lung function impairment and functional parameters did not differ between COPD patients with and those without metabolic syndrome. Additionally, the prevalence of osteoporosis and disease-specific health status were not altered by the presence of metabolic syndrome. Additionally, the prevalence of osteoporosis and disease-specific health status were not altered by the presence of metabolic syndrome, while metabolic syndrome has shown to contribute to an increased co-morbidity index.

Acknowledgments
AstraZeneca provided support in the form of a salary for author PLBB, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the authors are articulated in the ‘author contributions’ section.

Author Contributions
Conceived and designed the experiments: EFMW EPAR MAS. Performed the experiments: MTJG. Analyzed the data: MKB FMEF LEGWV EPAR. Wrote the paper: MKB.

References
1. Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD. Eur Respir J 33: 1165–1183.
2. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, et al. (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16: 63–70.
3. Mannino DM, Thorn D, Swensen A, Holguin F (2008) Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32: 962–969.
4. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, et al. (2012) Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186: 153–161.
5. Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23: 469–480.
6. Erkel RH, Grunty SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415–1420.
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683–689.
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al. (2002) The metabolic syndrome and total and cardiovascular mortality in middle-aged men. JAMA 288: 2709–2716.
9. Ribas PM, Lang W, Jaramillo SA, Jakicic JM, Stewart RJ, et al. (2007) Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. Diabetes Care 30: 2679–2684.
10. Ford ES, Li C (2006) Physical activity or fitness and the metabolic syndrome. Jama 298: 2709–2716.
11. Kinjo M, Setoguchi I, Solomon DH (2007) Bone mineral density in adults with the metabolic syndrome: analysis in a population-based U.S. sample. J Clin Endocrinol Metab 92: 4161–4164.
12. Wells G (2013) Metabolic syndrome and diabetes mellitus in COPD: European Respiratory Monograph.
13. Marquis K, Malais F, Dugay V, Bezeau AM, LeBlanc P, et al. (2009) The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 29: 226–232. Discussion 233–244.
14. Watz H, Waschki B, Kirsten A, Muller KC, Kretschmar G, et al. (2009) The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD. COPD 6: 414–420.
15. Yamaguchi T, Kanzawa I, Yamamoto M, Kurioke S, Yanouchi M, et al. (2009) Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. Bone 45: 174–179.
16. Feyereisl P, Scherer PE (2008) Metabolic syndrome. Adv Med 16: 63–70.
17. Krieger N, Zimmet P (2010) Metabolic syndrome. In: Globalization of the metabolic syndrome. Oxford University Press.
18. Krolewski AS, Pickering TG (2007) The metabolic syndrome and cardiovascular disease. Diabetes Care 30: 2310–2317.
19. Kritchevsky SB, Kiel DP, Hui SL, Kritchevsky DM, et al. (2009) Randomized controlled trial of exercise and weight loss in older osteoarthritic adults. Arthritis Care Res (Hoboken) 61: 749–757.
20. Metabolic School of Medicine and Dentistry. 2010. Micronutrients and the metabolic syndrome. Cell Metab 11: 536–538.
21. Modesti PA, Faggiano A, Turrini O, Rosolen G, Maiani G, et al. (2007) Association of the metabolic syndrome with impaired glucose tolerance and type 2 diabetes. Diabetes Care 30: 2650–2655.
22. Naveh E, Rabinovitch S, Kritchevsky SB, Kritchevsky DM, et al. (2009) The metabolic syndrome and the risk of mortality in older adults: the Health, Aging, and Body Composition Study. J Am Geriatr Soc 57: 1868–1874.
23. Pedersen AN, Pedersen NL, Rasmussen F, Agerholm-Larsen K, Pedersen O, et al. (2008) Association of the metabolic syndrome with impaired glucose tolerance, type 2 diabetes, and type 2 diabetes mellitus. Diabetes Care 31: 1231–1236.
24. Ribulz C, De Castellano M, De Simone G, De Feo D, Di Marzo F, et al. (2008) Association of the metabolic syndrome with cardiovascular disease and type 2 diabetes. Diabetes Care 31: 1231–1236.
25. Reid IR (2010) Fat and bone. Arch Biochem Biophys 503: 20–27.
26. Polosa R, Urosevic M, Ukebonta V, Joppa P, et al. (2011) Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. Bone 48: 1008–1014.
27. Ferrer M, Aleman J, Moreira J, Marrades RM, Khalaf A, et al. (1997) Chronic obstructive pulmonary disease and health-related quality of life. Ann Intern Med 127: 1072–1079.
28. Ketchersis CA, Schlussel MA, Mostert R, Huyer Abu-Saad H, Halfens RJ, et al. (1996) Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax 51: 39–43.
29. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Koyama H, et al. (1998) Comparison of discriminative properties among disease-specific questionnaires for measuring health-related quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 789–796.
30. Shoup R, Dalbey G, Warner S, Davies M, Connors M, et al. (1997) Body composition and health-related quality of life in patients with obstructive airways disease. Eur Respir J 10: 1576–1580.
31. Roser-Cruz M, Rosset J, Wiada T, Sakagami T, Ishimi M, et al. (2007) Stroke-independent association between metabolic syndrome and functional dependence, depression, and low quality of life in elderly community-dwelling Brazilian people. J Am Geriatr Soc 55: 374–382.
32. Sasai AG, Wadden TA, Sarver DB, Berkowitz RJ, Venable LG, et al. (2006) Metabolic syndrome and health-related quality of life in obese individuals seeking weight reduction. Obesity (Silver Spring) 14: 59–63.
33. Miura K, Kato N, Nitta H, Itoh T, Kikuc K, et al. (2007) Association of the metabolic syndrome with adipocyte tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD 4: 414–420.